Digital Disclosure of Alzheimer’s Genetic, Biomarker Results Noninferior to Telehealth

Older adults who learned their Alzheimer’s disease genetic and blood biomarker risks through a digital platform experienced anxiety and knowledge outcomes comparable to those who received the same information via telehealth, according to findings presented at a medical conference.

Digital Delivery Shows No Greater Distress than Video Visits

  • Digital vs. Telehealth: Receiving genetic and biomarker results online caused no greater distress than talking with a clinician over video.
  • Immediate Access: The trial addresses modern patient portals where individuals view complex lab values without instant context.
  • Minor Subgroup Differences: Carriers of the genetic risk factor showed slight, short-lived increases in negative reactions when using the digital platform.

Clinical Findings From the eSMARTER Trial

As demonstrated by the randomized eSMARTER trial and highlighted by MedPage Today, utilizing an online application to obtain Alzheimer’s biomarker and genetic data proved noninferior to receiving the same details via a telehealth session.

Between 1 and 7 days following the disclosure of APOE findings, assessments evaluating anxiety, condition-specific distress, and understanding of the disease achieved noninferiority thresholds regardless of whether participants were assigned to an automated software interface or a video consultation guided by a medical professional, explained Jessica Langbaum, PhD, representing the Banner Alzheimer’s Institute in Phoenix, during her presentation at the Clinical Trials on Alzheimer’s Disease meeting held in Boston.

Similar results emerged for phosphorylated tau 217 disclosure, Langbaum reported. These findings were also published in JAMA Neurology.

“We found that learning Alzheimer’s genetic and biomarker information from a digital platform is no less effective — in other words, no worse than — receiving this information from a clinician telehealth visit,” Langbaum told MedPage Today.

Digital Disclosure of Alzheimer's Genetic, Biomarker Results Noninferior to Telehealth
Photo: News-Medical

Under the United States 21st Century Cures Act, most medical test results must be made available to patients without delay, News-Medical reported. This means patients may see genetic and biomarker findings without a healthcare professional present, while APOE genotyping provides information on genetic susceptibility and blood-based biomarkers such as p-tau217 indicate underlying disease pathology.

“This is important given that most patients learn their test results from a report in their patient portal — often a static report or PDF, with limited to no additional information or context about their results and what they mean — and have to wait until their scheduled follow-up appointment to speak with their clinician,” Langbaum pointed out to MedPage Today.

Trial Demographics and Methodology

The eSMARTER trial included participants ages 60 to 80 who had previously undergone APOE genotyping without disclosure through the GeneMatch research enrollment program, passed psychological screening, and had internet access. Participants had a mean age of 68 and a mean Montreal Cognitive Assessment score of 19, with approximately 36% scoring below 19 and 67% identifying as women.

Study Arm Initial Participants Randomized Completed APOE Disclosure
Digital Platform 435 —
Clinician-Mediated Telehealth 216 —
Total Primary Analysis 666 651

The study randomized 216 participants to clinician-mediated APOE disclosure and 435 to digital disclosure, according to MedPage Today. Genetic test results were revealed first, and after 6 months, participants could choose p-tau217 disclosure through their assigned method, with a study physician communicating results in the telehealth group.

Outcomes Among Genetic Risk Carriers

Of 651 participants who received APOE disclosure, most were APOE4 carriers, including 58% heterozygotes, 10% homozygotes, and 32% noncarriers. Following the receipt of APOE findings, the online and video consultation groups showed comparable outcomes regarding overall Alzheimer’s-related knowledge levels, anxiety symptoms, and condition-specific distress.

Among APOE4 carriers, three specific variations were observed: the telehealth group experienced a greater decrease in condition-specific distress compared to the online cohort at the 1-to-7-day mark, though these variances remained minimal and did not endure over the long term; the digital cohort exhibited a higher average negative reaction upon discovering their APOE risk during the initial 1 to 7 days relative to the telehealth participants; and the video-based telehealth group reported slightly higher average satisfaction scores during that same 1-to-7-day window.

Digital disclosure was also associated with slightly higher negative responses to learning genetic risk, though these differences were small, unlikely to be clinically significant, and did not persist, News-Medical noted. Among APOE ε4 noncarriers, the study noted no significant differences in knowledge or psychological outcomes, with participants in this subgroup rating telehealth sessions more favorably.

Cognitive Impairment and No Internet Access Exclude Digital Delivery

Patients with active cognitive impairment or those who lack internet access were excluded from digital randomization screens, requiring clinical oversight for sensitive biomarker results.

Future Scaling of Patient Portals

The eSMARTER study shows that digital disclosure is an acceptable alternative to telehealth, Langbaum observed. These findings indicate that developers could build an adaptable software solution capable of integrating into existing medical record patient portals, thereby aiding individuals in interpreting and contextualizing their laboratory outcomes.

As the senior director research strategy at the Banner Alzheimer’s Institute and the director of the Arizona Alzheimer’s Disease Research Center, Jessica Langbaum, PhD focuses her research on Alzheimer’s disease prevention trials with an emphasis on primary prevention strategies.

Her work and that of her colleagues involve designing and conducting trials within the Alzheimer’s Prevention Initiative, a collaborative effort established by the Banner Alzheimer’s Institute to launch a new era in prevention research and accelerate the evaluation and approval of prevention therapies.

“We envision that these platforms can be used by clinicians and health systems to better support patients to navigate complex health information,” Langbaum said.

References

  • Langbaum, J. B., Erickson, C. M., Langlois, C. M., et al. (2026). Digital Delivery of Apolipoprotein E Genotype and Phosphorylated Tau 217 Results: The eSMARTER Randomized Clinical Trial. JAMA Neurology.
  • MedPage Today. Alzheimer’s Test Results Delivered Digitally Didn’t Increase Distress.
  • News-Medical. Your Alzheimer’s test results are ready online. Would you open them?
Photo of author

Health Desk

Health Desk at Archyde.

Arda Omit Nikolov From Squad After Suspension, Future Uncertain